MedTrace Logo

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

NCT03040427 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-07-27

Study results available
· View outcomes & findings →

Summary

The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.

Conditions

  • Cardiac Amyloidosis

Interventions

DRUG

F-18 florbetapir

Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    collaborator INDUSTRY

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Steven Nissen, MD · The Cleveland Clinic

  • Wael Jaber, MD · The Cleveland Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-08-21
Completion
2019-08-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03040427 on ClinicalTrials.gov